Patents by Inventor Stephen Scaringe

Stephen Scaringe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B)
    Publication number: 20120264813
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Proto-oncogene MET
    Publication number: 20120258888
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.
    Type: Application
    Filed: June 12, 2012
    Publication date: October 11, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Kinase Insert Domain Receptor (KDR)
    Publication number: 20120258889
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 11, 2012
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Interleukin-1 Receptor-associated Kinase 4 (IRAK4)
    Publication number: 20120252873
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 4, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting amyloid beta (A4) precursor protein (APP)
    Patent number: 8268985
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: September 18, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Catenin, Beta-1 (CTNNB1)
    Publication number: 20120220496
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting diacylglycerol O-acyltransferase homolog 2 (DGAT2)
    Patent number: 8247169
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: August 21, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting glucagon receptor (GCGR)
    Patent number: 8236942
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: August 7, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
    Patent number: 8232385
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: July 31, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting apolipoprotein B (APOB)
    Patent number: 8232386
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 31, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Connective Tissue Growth Factor (CTGF)
    Publication number: 20120184463
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 19, 2012
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting kinase insert domain receptor (KDR)
    Patent number: 8222395
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: July 17, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting proto-oncogene MET
    Patent number: 8222396
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: July 17, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting interleukin-1 receptor-associated kinase 4(IRAK4)
    Patent number: 8217162
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 10, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • SiRNA targeting catenin, beta-1 (CTNNB1)
    Patent number: 8198427
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 12, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting spleen tyrosine kinase
    Publication number: 20120135892
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
    Type: Application
    Filed: December 6, 2011
    Publication date: May 31, 2012
    Applicant: DHARMACON INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe
  • SIRNA TARGETING CATENIN, BETA-1 (CTNNB1)
    Publication number: 20120136144
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 31, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA targeting connective tissue growth factor (CTGF)
    Patent number: 8138329
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: March 20, 2012
    Assignee: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • siRNA Targeting Apolipoprotein B (APOB)
    Publication number: 20120065250
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB.
    Type: Application
    Filed: October 27, 2011
    Publication date: March 15, 2012
    Applicant: DHARMACON, INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • METHODS AND COMPOSITIONS FOR SELECTING SIRNA OF IMPROVED FUNCTIONALITY
    Publication number: 20120052487
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.
    Type: Application
    Filed: September 14, 2004
    Publication date: March 1, 2012
    Applicant: Dharmacon, Inc.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe